Jubilant Pharmova Limited has informed the Exchange regarding a press release dated November 10, 2026, titled "Jubilant Therapeutics Announces Oral Presentation of Preliminary Phase 1 Clinical Data for JBI-802, a First-in-Class Oral Dual LSD1/HDAC6 Inhibitor, in Essential Thrombocythemia and Related Myeloproliferative Neoplasms at the 68th ASH Annual Meeting".
EarningsCanvas
Loading your research…
Opening the latest published company and exchange records.